guidanc industri rheumatoid arthriti develop drug product treatment draft guidanc guidanc document di stribut comment purpos comment suggest regard draft document submit within 60 day public feder regist notic announc avail draft guidanc submit electron comment httpwwwregulationsgov submit written comment divis docket manag ment hfa305 food drug administr 5630 fisher lane rm 1061 rockvil md 20852 comment identifi docket number list notic avail publish feder regist question regard draft document c ontact cder dr nikolay p nikolov 301796 2300 cber offic co mmunic outreach develop 8008354709 3018271800 cdrh markham luke 3017965556 us depart health human servic food drug administr center drug evalu research cder center biolog evalu research cber center devic ra diolog health cdrh may 2013 clinicalmed revis 1 i8932dftdoc 051313 guidanc industri rheumatoid arthriti develop drug product treatment addit copi avail offic commun divis drug inform center drug evalu research food drug administr 10903 new hampshir ave bldg 51 rm 2201 silver spring md 209930002 tel 3017963400 fax 3018478714 email druginfofdahhsgov httpwwwfdagovdrugsguidancecomplianc egulatoryinformationguidancesdefaulthtm offic commun outrea ch develop hfm40 center biolog evalu research food drug administr 1401 rockvil pike suit 200n rockvil md 208521448 tel 8008354709 3018271800 email ocodfdahhsgov httpwwwfdagovbiologicsbloodvaccinesguidan cecomplianceregulatoryinformationdefaulthtm offic commun educ radiat program divis small manufactur intern consum assist hfz220 center devic radiolog health food drug administr 1350 piccard drive rockvil md 208504307 dsmica email dsmicacdrhfdagov dsmica fax 3014438818 tel manufactur assist 8006382041 3014436597 tel intern staff 3018273993 httpwwwfdagovmedicaldevicesdeviceregulationandguidanceguidancedocumentsdefaulthtm us depart health human servic food drug administr center drug evalu research cder center biolog evalu research cber center devic ra diolog health cdrh may 2013 clinicalmed revis 1 tabl content introduct 1 ii clinic develop program 2 dose dose regimen select considerations2 b efficaci consider 3 c safeti consider 5 drugdevic combin product consider 6 refer 8 contain nonbind recommend draft implement 1 guidanc industry1 2 rheumatoid arthriti 3 develop drug product treatment 4 5 6 7 8 draft guidanc final repres th e food drug administr fda current 9 think topic creat confer right person oper 10 bind fda public use altern pproach approach satisfi requir 11 applic statut regul want discuss altern approach contact fda 12 staff respons implement guidanc identifi appropri fda staff call 13 appropri number list titl page guidanc 14 15 16 17 18 introduct 19 20 purpos guidanc outlin fda current think principl clinic 21 develop relev doseselect ass ssment efficaci safeti support 22 approv drug product treatment patient rheumatoid arthriti ra also 23 address addit consider drug product develop drugdevic combin 24 product guidanc address nonc linic develop develop drug 25 product juvenil idiopath ic arthriti developmen biosimilar product 26 27 guidanc revis guidanc industri clinic develop program drug 28 devic biolog product tr eatment rheumatoid arthriti ra publish 29 februari 1999 2 final gu idanc replac februari 1999 30 guidanc reflect current think fda ra drug product develop 31 fda current think influenc clinic develop program conduct ra 32 sinc 1999 guidanc publish chang standard care ra 33 avail mani effect trea tment revis includ 34 35 dose dose regimen select thr oughout clinic de velop program 36 37 expect establish efficaci ra base sign symptom physic 38 function domain 1 guidanc prepar divis pulmonari allergi rheumatolog product center drug evalu research cder cooper center biolog evalu research cber center devic radiolog hea lth cdrh food drug administr 2 updat guidanc period make sure recent version guidanc check fda drug guidanc web page httpwwwfdagovdrugsguidancecompliancereg ulatoryinformationgu idancesdefaulthtm 1 contain nonbind recommend draft implement 39 40 use efficaci endpoint clinic mission prevent structur damag 41 progress 42 43 limit use placebo 44 45 use activ compar safeti efficaci trial 46 47 principl safeti assess 48 49 develop drugdevic combin product 50 51 guidanc discuss genera l issu statistica l analysi clinic trial design 52 topic address ich guidanc industri e9 statist principl clinic 53 trial e10 choic control group relat issu clinic trial respect 54 guidanc focus specif drug product de velop trial design issu 55 uniqu studi ra 56 57 fda guidanc document includ guid anc establish legal enforc 58 respons instead guidanc describ th e agenc current thinki ng topic 59 view recommend unless spec ific regulatori stat utori requir 60 cite use word agenc guidanc mean someth suggest 61 recommend requir 62 63 64 ii clinic develop program 65 66 dose dose regimen select consider 67 68 select nomin dose dose regimen fundament compon drug 69 product develop recommend dose dose regimen base 70 benefittorisk assess support avail data gather throughout 71 develop program import find appropri nomin dose dose regimen 72 produc efficaci accept long shortterm safeti profil mani drug 73 product intend treat ra potenti caus seriou doserel advers reaction 74 opportunist infecti on malign may appar shortterm 75 clinic trial see section iic disc ussion clinic sa feti databas dose 76 rang explor begin earli develop program often continu 77 throughout definit efficaci safeti studyi smaller earli doserang exploratori 78 studi may adequ select singl dose singl dose regimen 79 80 follow consid design doserang studi 81 82 studi wide rang dose dosi ng regimen base pharmacokinet 83 relev pharmacodynam consider 84 2 contain nonbind recommend draft implement 85 use endpoint sensit chang pr ovid better discriminatori power dose 86 87 respons assess clinic endpoint su ch acr20 respons criteria may optim purpose3 dichotom endpoint use 88 89 proport respond small group pa tient could unrelia ble endpoint das28 4 hybrid acr response5 continu variab le may sensit 90 chang provid suitabl altern acr respond index support 91 pharmacodynam marker consid ed scientif justifi 92 93 time evalu assess steep part doser spons curv dose 94 respons assess endpoint evalu time point therapeut 95 plateau like eg week 2 8 better captur possibl e differ 96 dose later time point evalu eg 12 week may inform estim 97 clinic effect chronic use 98 99 b efficaci consider 100 101 meet regulatori standard approv un der section 505d feder food drug 102 cosmet act sponsor must provid substan tial evid efficaci enrol patient 103 popul demonstr accept riskben efit profil drug product 21 usc 104 355d studi one dosedos regimen use activ compar 105 definit studi facilit interpr tation efficaci overal riskbenefit 106 evalu section outlin principl sponsor follow assess efficaci drug 107 product treatment ra 108 109 1 establish efficaci key ra domain market approv drug product 110 treatment ra sponsor demonstr substanti evid efficaci 111 key ra domain clinic respons physic function 112 113 clinic respons acr20 respons criteria continu accept measur 114 demonstr reduct ra diseas activ addit higher level respons 115 measur acr50 acr70 respons rate measur low diseas 116 activ das28 less 26 use support evid efficaci 117 clinic spons domain 118 3 acr20 50 70 respons criteria american colleg rheumatolog respons criteria dichotom composit endpoint indic proport patient least 20 50 70 percent improv number tender swollen joint three remain five acr coreset measur patient pain patient global assess diseas physician global assess diseas physic function assess health assess questionnairedis dex haqdi acut phase reactant 4 das28 diseas activ score 28 mathemat ly calcul continu composit endpoint differenti weight given follow componen ts tender joint count 28 joint swollen joint count 28 joint acut phase reactant patient global assess arthriti 5 hybrid acr respons continu score mean improv core set measur combin acr20 acr50 acr70 respons rate american colleg rheumatolog committe reevalu improv criteria 2007 3 contain nonbind recommend draft implement 119 physic function health assess questionnairedis index haqdi 120 use demonstr improv physic function6 121 122 data 12week placebocontrol clinic trial gener would accept 123 provid evid efficaci clinic spons physic function domain 124 125 2 domain note item 1 market approv ra 126 foundat demonstr efficaci includ clinic respons physic 127 function use measur acr20 respons rate haqdi respect 128 demonstr efficaci domain import patient health care 129 provid provid character efficaci drug product 130 util clinic practic domain includ 131 132 prevent structur damag progress reduct radiograph evid 133 structur damag progress import predictor longterm benefit 134 delay prevent progress disa biliti relat ra radiograph data 135 use valid score method use demonstr efficaci 136 domain howev demonstr prevent structur damag progress 137 radiograph becom increas ly difficult sever reason 138 139 use placebo control longterm trial usual 6 month longer 140 trial done past demonstrat e effect radiograph outcom 141 longer feasibl see item 3 142 143 extent progress plac ebo group low shortterm 144 trial thu observ treatment e ffect size investig drug 145 product small difficult detect 146 147 limit current analysi method 148 149 therefor sponsor consid altern studi design eg activ compar 150 studi appli differ measur eg proport patient radiograph 151 progress altern analyt met hod assess radiograph benefit 152 imag modal magneti c reson imag ultrasonographi 153 may allow demonstr benefit structur damag progress 154 control studi may shorter studi use radiograph data howev 155 modal valid outcom measur ra date 156 157 clinic remiss remiss import goal ra treatment american 158 colleg rheumatologyeuropean l eagu rheumat acreular 159 provision definit remi ssion criteria may accept use ra clinic 160 develop program acreular 2011 patient achiev remiss 161 follow provid inform th e durabl remiss respons 6 haqdi assess degre difficulti patient experienc past week eight domain daili live activ dress groom aris eat walk hygien reach grip activ 4 contain nonbind recommend draft implement 162 163 aspect ra oth r outcom measur may inform addit 164 endpoint ra clinic develop pr ogram sponsor provid support 165 evid develop select measur sponsor also provid 166 justif use given measur includ import clinic 167 relev nonredund propos outcom measur 168 169 3 use placebo assess efficaci domain may requir longterm 170 control clinic trial data howev avail effect ra therapi 171 shift paradigm treatment ear ly establish ra focu earli 172 control diseas activ singh 2012 provid rational limit 173 exposur patient placebo ineffec tive therapi prolong period time 174 ie beyond 12 week american colleg rheumatolog 2011 therefor studi 175 longer 12 week includ activ co mparat cont rol provis 176 escap rescu treatment patient activ diseas 177 178 c safeti consider 179 180 size safeti databas drug biolog product meet minimum 181 recommend outlin ich guidanc industri e1a extent popul 182 exposur assess clinic safet drug intend long term treatment nonlif 183 threaten condit howev drug product develop ra may potenti 184 seriou advers effect may caus concern unfortun durat trial would 185 support demonstr efficaci may su fficient adequ safeti assess 186 short durat placebocontrol period ie 12 week would limit amount 187 control safeti data therefor better character longterm safeti profil 188 investig drug product uncommon advers event event longer latenc 189 period opportunist infect lignanc may request premarket safeti 190 databas larger size longer durat th recommend ich e1a new molecular 191 entiti intend chronic treatment ra 192 193 request like includ least 1 year control safeti data new molecular entiti 194 activ compar arm facilit interp retat data sa feti data shorter 195 durat may consid drug product new molecular entiti reason 196 compar arm includ use multipl dose investig drug product 197 standardofcar treatment definit clinic trial inclus one dose 198 investig drug product provid importa nt doserespons inform regard 199 efficaci safeti safeti issu terest sponsor consid independ 200 adjud process need detail specif monitor may chang new data 201 emerg sponsor encourag discuss plan specif safeti monitor 202 fda earli stage drug product develop 203 204 approach analys safeti data take account complex studi 205 design eg crossov respons escap prov ision crossov design addit 206 approach analys integr safeti data take account possibl differ 207 patient popul andor differ studi design multipl studi 5 contain nonbind recommend draft implement 208 209 drugdevic combin product consider 210 211 therapi develop treatment ra includ drug product may requir parenter 212 administr use accessori deliveri unit eg autoinjector case 213 manufactur drug product ensur accessori deliveri unit approv 214 clear market devic regulatori process eg 510k process premarket 215 approv center devic radiolog health accessori deliveri unit 216 alreadi approv cl ear market approv clear least 217 concurr drug product approv 218 219 characterist drug product deliveri devic meet 220 definit combin product 21 cfr 32e center primari jurisdict 221 premarket review regul combin product determin base 222 procedur set forth 21 cfr 34 exampl e primari mode action 223 combin product drug product th e entir combin product assign 224 center drug evalu research combin product gener need 225 one market applic eg new drug pplicationbiolog licens applic 226 sponsor encourag contact offic combin product w ith gener question 227 regard drug product jurisdicti regulatori pathway drugdevic combin 228 product 229 230 gener drugdevic combin pr oduct complet chemistri 231 manufactur control databas devic design develop substanti 232 complet clinic develop program support efficaci safeti entir combin 233 product anticip tobemarket drugdevic combin product use 234 pivot studi support efficaci safeti combin product market 235 approv inform drugdevic inject develop see draft guidanc 236 237 industri fda staff technic consider pen je relat injector intend use drug biolog product 7 guidanc includ info rmation issu 238 rootcaus analys devic lfunction may lead potenti al improv devic 239 240 likewis current good manufactur pract ice requir combin product provid 21 cfr part 4 subpart 8 241 242 develop ra drug deliveri syst em sponsor take consider 243 characterist intend user popul use environ product intend 244 selfadministr ra pa tient devic durabl dexter visual 245 acuiti requir use devic hould within capabl ra patient human factor 246 studi assess user late hazard conduct earli develop ideal 247 conduct key doserang safeti efficaci studi consider 7 final guidanc represen fda current think topic recent version guidanc check fda drug guidanc web page httpwwwfdagovdrugsguidancecompliancereg ulatoryinformationgu idancesdefaulthtm 8 see httpswwwfederalregist govarticles20130122201301068c urrentgoodmanufacturingpractic requirementsforcombinationproduct 6 contain nonbind recommend draft implement 248 human factor studi see draft guidanc industri fda staff appli human factor 249 usabl engin optim medic devic design 9 250 251 ongo evalu devic perform incorpor pivot studi 252 combin product exampl eval uation includ king patient report 253 devic perceiv broken malf unction return devic 254 evalu identif problem de vice use perform also evalu 255 direct question defin protocol addit small number devic eg 256 100 appar function normal hould collect use evalu 257 vitro perform test ensur devic robust 258 259 although use tobemarket formul drugdevic combin product 260 throughout develop optim acknowledg chang drug product deliveri 261 system may occur chang formul excipi devic compon may affect 262 drug product deliveri characterist ic clinic perform drugdevic combin 263 product extent clinic data need support chang depend natur 264 chang develop stage exampl transit prefil syring 265 autoinjector deliveri system involv followin g minimum 1 hu man factor studi 266 evalu potenti user late risk modifi comb inat product 2 pharmacokinet 267 bridg studi demonstr similar deliveri drug product th e biospac across 268 rang bodi weight 3 reallif patient handl experi assess devic 269 perform discuss depend extent propos chang addit 270 clinic data may need support efficaci safeti includ immunogen 271 272 sponsor encourag discu type issu appr opriat market applic 273 fda earli develop feasibl 274 9 final guidanc represen fda current think topic recent version guidanc check fda devic guidanc web page httpwwwfdagovmedicaldevicesdev iceregulationandguidanceguidancedocumentsucm198577htm final guidanc supersed guidanc ndustri fda premarket design control review medic devic usesafeti incorpor human factor engin risk manag recent version guidanc chec k fda devic guidanc web page httpwwwfdagovmedicaldevicesd eviceregulationandguidanceguidancedocumentsucm070271htm 7 contain nonbind recommend draft implement 275 refer 276 277 literari 278 279 acreular 2011 provision defini tion remiss rheumatoid arthriti clinic 280 trial arthriti rheum mar63357386 281 282 american colleg rheumatolog 2011 clinic trial prioriti design confer juli 283 2223 2010 arthriti rheu aug63821516 284 285 american colleg rheumatolog committe reevalu improv criteria 2007 286 propos revis acr20 hybrid measur american colleg rheumatolog 287 respons arthriti rheu mar 15572193202 288 289 singh ja 2012 updat 2008 american colleg rheumatolog recommend 290 use diseasemodifi antirheumat drug biolog agent treatment 291 rheumatoid arthriti arthriti care re may64562539 292 293 guidanc 294 295 draft guidanc industri fda staff appli human factor usabl engin 296 optim medic devic design 297 298 draft guidanc industri fda staff technic consider pen jet relat 299 injector intend use drug biolog product 300 301 guidanc industri fda premarket design control review medic devic use 302 safeti incorpor human facto rs engin risk manag 303 304 ich guidanc industri e1a extent popul expo ure assess clinic safeti 305 drug intend longterm treatm ent nonlifethreaten condit 306 8